Physician profile
Adeline Monger
NPI 1700593654
$8,914.87
in general payments reported to CMS, 2019-2025
33 companies · $2,022 in 2025
The $2,022 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $40.99 · 2023: $3,263 · 2024: $3,589 · 2025: $2,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,873.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,205.91 | 2023-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $1,064.92 | 2023-2025 | Qelbree, Qelbree |
| Abbvie INC. | $1,017.50 | 2023-2025 | |
| Corium, LLC | $871.72 | 2023-2025 | Azstarys, Azstarys |
| Otsuka America Pharmaceutical, INC. | $597.44 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Axsome Therapeutics, INC. | $495.94 | 2023-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $438.09 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Validus Pharmaceuticals LLC | $349.42 | 2023-2025 | Equetro, Equetro, Raldesy |
| Ironshore Pharmaceuticals INC. | $325.36 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $321.83 | 2023-2025 | Dyanavel Xr |
| Lundbeck LLC | $245.65 | 2023-2025 | Rexulti |
| Noven Therapeutics, LLC | $215.61 | 2023-2024 | Xelstrym, Secuado |
| Neurocrine Biosciences, INC. | $207.91 | 2023-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $187.24 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $161.05 | 2025 | Jornay Pm |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $150.60 | 2023-2024 | Spravato, Invega Sustenna |
| Bausch Health US, LLC | $129.20 | 2023-2025 | Aplenzin, Wellbutrin |
| Indivior INC. | $128.38 | 2023-2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $123.18 | 2023-2025 | Trintellix |
| Almatica Pharma LLC | $103.30 | 2023-2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $103.04 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $101.14 | 2023-2024 | Austedo Xr, Uzedy |
| Idorsia Pharmaceuticals US INC | $85.52 | 2023-2025 | Quviviq, Quviviq |
| Neos Therapeutics, LP | $62.89 | 2023-2025 | Adzenys Xr-Odt, Metadate Cd |
| Biogen, INC. | $39.10 | 2024 | Vumerity |
| Avion Pharmaceuticals | $37.24 | 2023 | Methylphenidate Hydrochloride |
| Soleno Therapeutics, INC. | $28.52 | 2025 | Vykat Xr |
| Azurity Pharmaceuticals, INC. | $27.09 | 2023-2024 | Horizant, Horizant |
| Livanova USA, INC. | $22.72 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Braeburn INC. | $22.11 | 2023 | Brixadi |
| Tempus Ai, INC | $17.59 | 2024 | |
| Vertical Pharmaceuticals, LLC | $14.67 | 2025 | Relexxii |
| Merck Sharp & Dohme LLC | $12.99 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adeline Monger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.